DHB, short for dihydroboldenone and also sold under the name 1-testosterone, is a synthetic anabolic-androgenic steroid that was never approved for medical use in any country. It is chemically a 5α-reduced form of boldenone and a derivative of dihydrotestosterone, classified as a designer steroid with moderate androgenic activity and reportedly high anabolic effects. Because it exists entirely outside pharmaceutical channels, everything about its real-world use comes from underground manufacturing, self-experimentation, and a handful of laboratory studies on related compounds rather than clinical trials on humans.
The Chemistry Behind DHB
DHB’s full chemical name is 17β-hydroxy-5α-androst-1-en-3-one. That name tells you it belongs to the androstane family of steroids, sharing a core four-ring carbon skeleton with testosterone and dihydrotestosterone (DHT). What makes DHB distinct is a double bond at the 1,2 position of the A-ring combined with 5α-reduction, a structural modification that changes how the molecule interacts with androgen receptors and metabolic enzymes. The cypionate ester version, dihydroboldenone cypionate, acts as a prodrug: after injection, the ester is cleaved off in the body, releasing the active DHB molecule over time.1Journal of Molecular Structure. Structural studies of some androstane based prodrugs
Its relationship to boldenone (the steroid in Equipoise, a veterinary drug) is straightforward: boldenone has a 1,2-double bond but is not 5α-reduced, while DHB is the 5α-reduced version of that same molecule. Think of it as what happens when the body’s 5α-reductase enzyme acts on boldenone, similar to how DHT is the 5α-reduced product of testosterone. The 5α-reductase enzyme family was first identified in steroid metabolism in the early 1950s, and the recognition that 5α-reduced steroids can be more potent than their parent compounds came later, in the 1960s.2PubMed Central. The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases DHB follows this general pattern, being considered more anabolic at the receptor level than boldenone itself.
Why People Use It
DHB has gained a niche following among bodybuilders and strength athletes primarily because of its reputation for producing lean muscle gains without the water retention or estrogenic side effects associated with many other anabolic steroids. Because DHB is already 5α-reduced, it cannot be further reduced by 5α-reductase in tissues like the scalp or prostate. For users who are concerned about hair loss or prostate enlargement from steroids that convert to DHT in those tissues, this is seen as an advantage. And because DHB’s structure resists conversion by the aromatase enzyme into estrogen, users typically do not experience gynecomastia (breast tissue growth) or significant bloating at moderate doses.
The compound is structurally close to methenolone, the active steroid in Primobolan. Methenolone is essentially DHB with a methyl group added at the 1-position. Research measuring how strongly various anabolic-androgenic steroids bind to androgen receptors in skeletal muscle found that methenolone binds with appreciable affinity, ranking between nandrolone and testosterone in receptor binding strength.3PubMed. Relative binding affinity of anabolic-androgenic steroids: comparison of the binding to the androgen receptors in skeletal muscle and in prostate, as well as to sex hormone-binding globulin Since DHB and methenolone share the same core structure, users and underground steroid community guides often extrapolate that DHB should behave similarly at the receptor, though direct binding studies on DHB itself in published literature are extremely scarce.
In practical terms, people turn to DHB when they want a steroid that promotes muscle hardness and moderate mass gains without the pronounced androgenic side effects of trenbolone or the water-retaining effects of testosterone at higher doses. It is almost always used as part of a multi-compound “stack” rather than as a sole agent, typically alongside a testosterone base.
Injection Pain and Administration
One of the most frequently discussed downsides of DHB in user communities is severe post-injection pain, commonly called “PIP.” This is not a trivial complaint. Many users describe DHB injections as significantly more painful than those of testosterone or nandrolone, with soreness, swelling, and even temporary difficulty using the injected muscle lasting several days. The pain appears related to DHB’s chemical properties in oil solution: the compound has a relatively high melting point and can fall out of solution or cause local irritation in muscle tissue.
To mitigate this, underground labs sometimes brew DHB at lower concentrations (typically 100 mg/mL rather than the 200 mg/mL common for many other steroids), use carrier oils with better solvency like miglyol or ethyl oleate, or add small amounts of guaiacol as a solvent. Even with these adjustments, many users report that DHB remains among the most uncomfortable steroids to inject. This injection-site reaction is a local inflammatory response, not an infection, though it can be difficult for users to tell the difference in the moment. The severity of PIP is a major reason why DHB, despite its appealing side-effect profile on paper, has not achieved the mainstream popularity of compounds like testosterone enanthate or nandrolone decanoate.
Liver and Organ Risks
DHB is not a 17α-alkylated steroid, which means it does not carry the specific form of liver toxicity associated with oral steroids like methandrostenolone (Dianabol) or stanozolol (Winstrol). The 17α-alkylation that makes those steroids survive first-pass metabolism through the liver is also what makes them directly hepatotoxic. DHB, injected as its cypionate ester, bypasses this issue.
That said, all anabolic-androgenic steroids can affect the liver when used at supraphysiological doses for extended periods. A review of AAS-induced liver injury found that testosterone and its derivatives have been linked to a specific pattern of cholestasis (bile flow obstruction), peliosis hepatis (blood-filled cysts in the liver), and both benign and malignant liver tumors.4PubMed Central. Anabolic androgenic steroid-induced liver injury: An update The mechanisms behind these effects include disruption of antioxidant defenses in liver cells and upregulation of bile acid production. While the risk is highest with oral 17α-alkylated steroids, injectable compounds are not zero-risk, particularly during prolonged use or when stacked with multiple compounds that stress the liver simultaneously.
Beyond the liver, long-term supraphysiological AAS use has documented effects on the cardiovascular system, including unfavorable shifts in cholesterol (lower HDL, higher LDL), increased left ventricular mass, and elevated blood pressure. DHB users face these same systemic risks. The fact that DHB does not aromatize to estrogen may actually work against cardiovascular health in this context, because estrogen has some protective effects on blood vessel function and cholesterol profiles. A steroid that suppresses natural testosterone production (and therefore reduces endogenous estrogen via aromatization) without providing any estrogenic activity of its own can leave the user in a state of very low estrogen, which is not benign.
Hormonal Suppression and Recovery
Like every exogenous anabolic steroid, DHB suppresses the body’s own production of testosterone through negative feedback on the hypothalamic-pituitary-gonadal axis. When you introduce a potent androgen from outside, your brain registers the elevated androgen signal and dials down the hormones (LH and FSH) that tell the testes to produce testosterone. This suppression begins within days of starting a cycle and becomes profound within weeks.
The concern is what happens after you stop. A case-control study comparing former AAS users to controls found that men who had previously used anabolic steroids still showed significantly lower total and free testosterone levels years after quitting. Among former users, about 27% had total testosterone below the clinical lower limit, compared to zero among the control group. Gonadotropins (the signaling hormones from the pituitary) were also suppressed in current users, alongside reductions in inhibin B and anti-Müllerian hormone, both markers of testicular function.5PLOS ONE. Former Abusers of Anabolic Androgenic Steroids Exhibit Decreased Testosterone Levels and Hypogonadal Symptoms Years after Cessation: A Case-Control Study
This finding is sobering for anyone using DHB or any other AAS with the assumption that their hormone levels will bounce back to normal after a “post-cycle therapy” protocol. While many users do recover, a meaningful fraction do not fully recover even years later. The risk of lasting hypogonadism is real and is one of the most consequential health considerations with any steroid cycle, including those centered around DHB.
Legal Status
In the United States, anabolic steroids became Schedule III controlled substances under the Anabolic Steroids Control Act of 1990. Designer steroids, which include compounds with chemical structures “derived from, or substantially similar to” existing controlled anabolic steroids, were further targeted by the Designer Anabolic Steroid Control Act of 2014. That law classified 25 additional designer steroids as controlled substances, many of which had been sold in over-the-counter supplements.6Human Kinetics Journals. The Third Time Is a Charm: News Media, Policy Dynamics, and the Designer Anabolic Steroid Control Act 1-Testosterone (DHB’s common market name) was among the compounds that fell under this regulatory umbrella. Possessing, distributing, or manufacturing DHB without a valid prescription (which, practically speaking, does not exist since no pharmacy dispenses it) is a federal offense.
Internationally, DHB falls under similar restrictions in most countries. The United Kingdom classifies anabolic steroids as Class C drugs, making supply and intent to supply illegal, though personal possession is not a criminal offense. Australia, Canada, and most EU member states treat anabolic steroids as controlled or prescription-only substances. In every jurisdiction, the compound’s status as a non-pharmaceutical designer steroid means there is no legal, regulated supply chain.
What You Actually Get From Underground Labs
Since DHB has no legitimate pharmaceutical manufacturer anywhere in the world, every vial in circulation comes from an underground laboratory. The quality control problems with underground-produced steroids are well-documented and serious. A systematic review and meta-analysis of published analytical studies on black-market anabolic steroids found that roughly 36% of products tested were outright counterfeit, and an additional 37% were substandard in quality. Products could contain no active ingredient at all, a different active ingredient than labeled, more or fewer milligrams than declared, or additional unlisted compounds.7PubMed Central. Fake anabolic androgenic steroids on the black market – a systematic review and meta-analysis on qualitative and quantitative analytical results found within the literature
Earlier forensic analyses of illegally distributed steroids reinforced this picture. In one study, 15 out of 42 products seized from illegal channels did not contain the ingredients declared on their labels.8Journal of Forensic Sciences. Black Market in Anabolic Steroids—Analysis of Illegally Distributed Products For a niche compound like DHB, which is less commonly produced than staples like testosterone enanthate or trenbolone acetate, the risk of receiving a mislabeled or contaminated product is arguably even higher. Fewer labs make it, fewer users are able to verify its identity through third-party testing, and the financial incentive to substitute a cheaper raw material is strong.
Some users send their vials to analytical testing services that have emerged alongside the underground steroid market. These services use techniques like high-performance liquid chromatography to verify the identity and concentration of the active ingredient. While this is better than blind trust, it only tests a sample from one vial and says nothing about sterility, endotoxin levels, or heavy metal contamination, all of which matter for something you are injecting into muscle tissue.
How DHB Compares to Commonly Used Steroids
Users often weigh DHB against Primobolan (methenolone enanthate) because of the structural similarity. Primobolan is one of the few anabolic steroids that has a history of legitimate medical use and is often regarded as one of the “milder” compounds. DHB is seen in the underground community as a more cost-effective alternative that delivers similar quality of gains: lean tissue without water retention, minimal estrogenic effects, and lower androgenic load compared to trenbolone or high-dose testosterone. The trade-off is the injection pain and the fact that Primobolan has a track record of clinical data, however limited, while DHB has virtually none.
Compared to nandrolone (Deca-Durabolin), DHB does not convert to a weaker metabolite in androgenic tissues the way nandrolone converts to dihydronandrolone. Nandrolone’s conversion gives it an unusual profile: strongly anabolic in muscle but relatively mild in skin, hair, and prostate. DHB achieves a different version of “mild on androgenic tissues” by already being 5α-reduced, so it simply cannot undergo further conversion. But nandrolone has its own well-known issue: it and its metabolites suppress natural testosterone production especially deeply and can linger in the body for many months, making post-cycle recovery notoriously slow. DHB’s cypionate ester clears faster, which users consider a practical advantage.
Against trenbolone, DHB is not even in the same conversation for raw potency. Trenbolone is one of the most powerful anabolic steroids ever synthesized, with receptor binding affinity several times that of testosterone. It also comes with a proportionally severe side-effect burden: insomnia, night sweats, anxiety, cardiovascular stress, and aggressive mood changes. People who choose DHB over trenbolone are generally choosing a more moderate risk-to-reward ratio, accepting slower and less dramatic results in exchange for fewer acute side effects.
Dosing Practices in the Underground Community
Without clinical trials, every dosing guideline for DHB comes from self-experimentation and anecdotal reporting on bodybuilding forums and private groups. Commonly discussed doses range from 200 mg to 400 mg per week, injected in two or three divided doses to keep blood levels more stable and, pragmatically, to reduce the volume injected at any single site (which helps manage the injection pain problem). Some users push doses higher, but reports suggest that the pain and inflammation at the injection site become a limiting factor before other side effects do.
Cycle lengths typically run 12 to 16 weeks, similar to other injectable steroids with longer esters. Users almost universally pair DHB with a testosterone base, because DHB’s suppression of natural testosterone production means that without exogenous testosterone, they would quickly find themselves with inadequate androgen and estrogen levels. This is especially important given that DHB does not aromatize: without some source of estrogen, users risk joint pain, mood disturbance, low libido, and the cardiovascular consequences of chronically low estrogen discussed earlier.
The Odd Status of a Steroid Without Clinical Data
Most anabolic steroids in circulation, even those used illicitly, have some history of pharmaceutical development. Testosterone, nandrolone, oxandrolone, stanozolol, and methenolone were all developed by pharmaceutical companies and studied in clinical settings before finding their way into bodybuilding. DHB is unusual in that it was identified as a designer steroid without ever passing through that process.1Journal of Molecular Structure. Structural studies of some androstane based prodrugs This means there are no published human pharmacokinetic studies, no dose-finding trials, no safety monitoring data, and no formal toxicology work specific to this compound.
What users rely on instead is a combination of structural analogy (it looks like methenolone, so it probably behaves like methenolone), general AAS pharmacology (all androgens suppress the axis, all affect lipids, etc.), and collective anecdotal experience. This approach is not irrational, but it has real blind spots. Subtle differences in molecular structure can produce meaningful differences in receptor selectivity, metabolic pathways, and tissue-specific effects that only formal study would reveal. The history of pharmacology is full of compounds that looked safe by analogy until they were actually studied and turned out to behave unexpectedly. DHB users are, in a very real sense, running an uncontrolled experiment on themselves with a compound whose specific behavior in the human body has never been rigorously characterized.